Furthermore, in the head‐to‐head BRIGHT RCT, a 24 weeks treatment of Gla‐300 was compared to insulin degludec (IDeg) and demonstrated similar glycaemic control improvement, where Gla‐300 showed lower hypoglycaemic events during titration period.20 In the CONCLUDE trial, which was recently presented at the European Association for the Study of Diabetes (EASD), there was no statistical difference in the primary end‐point of number of severe or blood glucose confirmed symptomatic hypoglycaemia episodes between patients who initiated IDeg compared to Gla‐300 initiators.21 The gene discussed is INS; the disease is diabetes mellitus.